“Translational Regenerative Medicine market set to grow to $76bn by 2023” says new Visiongain report

07 February 2019
Pharma

Visiongain has launched a new pharma report Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

The high potential earning for companies from products aimed at repairing organs and tissues has led to an increase in the attention given to regenerative medicine research. Regenerative medicine (RM) is viewed as possessing the ability to provide therapeutic products targeted at multiple disease classes, such as cardiovascular, dermatological, and orthopaedic conditions. Developments in stem cell therapies and tissue engineering in particular may catalyse rapid growth in the translational regenerative medicine market over the next decade and beyond.

The lead analyst of the report commented "Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific. Partly, this is due to a desire to demonstrate excellence in national biotechnology industries, especially in emerging markets wanting to show progress in moving towards a knowledge-based economy. Governments are also concerned about obtaining a share in the global healthcare market of the future, when TRM products may be expected to overtake other types of treatment in the field of medicine, delivering both improved clinical outcomes and cost savings."

Leading companies featured in the report include Athersys, Inc., Avita Medical, AxoGen, Inc., MEDIPOST Co., Ltd., NuVasive, Astellas Pharma, Organogenesis Holdings Inc., Osiris Therapeutics, Inc. and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Clinical Trial Supply and Logistics market for pharma set to grow to $26bn by 2024” says new Visiongain report

Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs.

18 April 2019

Read

“Global Biosimilar Drugs market set to grow to $57bn by 2023” says new Visiongain report

The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature.

17 April 2019

Read

“Global Drug Discovery Outsourcing market set to grow to $45bn by 2024” says new Visiongain report

A major restraint in the global drug discovery outsourcing market comes from the fact that it is quickly becoming saturated, with many contract research organisations offering poorly differentiated services.

16 April 2019

Read

“Global Dermatological Drugs market set to grow to $36bn by 2024” says new Visiongain report

The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas.

15 April 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1